10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In another high profile failure for the fatty liver disease sector, USA-based Conatus Pharmaceuticals has announced disappointing top-line results from the company’s Phase IIb ENCORE-NF clinical trial in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis. 25 March 2019
Shortly after announcing its US filing for oral semaglutide, Danish diabetes giant Novo Nordisk has published positive Phase III data for the glucagon-like peptide-1 (GLP-1) analog in the Journal of the American Medical Association (JAMA). 25 March 2019
Continuing is recent flurry of licensing deals, Japan’s largest drugmaker Takeda has now entered into a research and licensing agreement with South Korea’s LegoChem Bioscience for the development of antibody-drug conjugates in immuno-oncology (I-O). 25 March 2019
US biotech firm bluebird bio on Friday officially opened its first wholly-owned manufacturing facility in Durham, North Carolina, that will produce lentiviral vector for the company’s investigational gene and cell therapies. 25 March 2019
Just a day after development partner Biogen revealed the Phase III failure of aducanumab, Japan’s Eisai has announced the start of late stage testing for another runner in the firms’ stable of Alzheimer’s candidates, BAN2401. 22 March 2019
Despite Brexit uncertainty, investment in the UK’s biotech sector has gone up 65% since 2016, with annual investment reaching £2.2 billion ($2.9 billion) in 2018. 22 March 2019
Janssen Pharmaceutica has submitted a Type II variation application to the European Medicines Agency (EMA) for a combination therapy for multiple myeloma. 22 March 2019
In the wake of the shocking failure of Biogen and Eisai’s aducanumab in Alzheimer’s, Canadian toxic oligomer specialist ProMIS Neurosciences has called for attention to be paid to its favored therapeutic approach. 22 March 2019
UK pharma major GlaxoSmithKline on Thursday announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate. 22 March 2019
Canadian preclinical stage company Ovensa today announce that it has entered into a collaboration agreement with Japan’s Takeda Pharmaceutical (TYO: 4502) to evaluate Ovensa's proprietary nanomedicine platform called Triozan for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model. 21 March 2019
Millions of people affected by Alzheimer’s disease were dealt a cruel blow on Thursday as the developers of aducanumab, a much-anticipated late stage candidate, announced the discontinuation of Phase III testing. 21 March 2019
In another move by big pharma into gene therapy, US giant Pfizer has acquired a 15% equity interest in privately-held French gene therapy biotech Vivet Therapeutics and secured an exclusive option to acquire all outstanding shares. 21 March 2019
Ireland-headquartered Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for Sunosi (solriamfetol) to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). 21 March 2019
People with Alzheimer’s who use the antiepileptic drugs phenytoin, carbamazepine, valproic acid and pregabalin were associated with an increased risk of pneumonia. 21 March 2019
The purse strings remain loose for Boston, USA-based Alexion Pharmaceuticals, with the announcement of two new pipeline-boosting collaborations in Europe. 21 March 2019
US biotech major Celgene has become the latest drugmaker to team up with Exscientia, a privately-owned UK-based company that uses artificial intelligence (AI) in drug discovery. 21 March 2019
Danish diabetes giant Novo Nordisk has filed for US approval for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet. 20 March 2019
Japan’s largest drugmaker Takeda Pharmaceutical has out-licensed global development, manufacturing and commercialization rights to serabelisib and two additional PI3Kα-specific inhibitors to privately held Petra Pharma. 20 March 2019
Belgium’s PDC*line Pharma has signed an exclusive licensing and option agreement with LG Chem Life Sciences, the life sciences division of LG Chem. 20 March 2019
UK biotech services firm Abzena has signed an agreement to support an integrated CMC program with Lipum, a Sweden-based company developing treatments for chronic inflammatory diseases. 20 March 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024